Status: Not yet recruiting

Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

The purpose of this study is to determine the objective response rate (ORR) to lorigerlimab in patients with refractory pancreatic ductal adenocarcinoma (PDAC) and pathogenic germline variants (PGVs) in breast cancer type 1 or 2 susceptibility protein (BRCA1/2), Partner and Localizer of BRCA2 (PALB2) and radiation sensitive protein 51 C or D (RAD51C/D).

Participants needed: 40

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Peter Hosein, MDUpdated: May 4, 2026Locations: 1

Eligibility criteria

Voluntarily agree to participate by giving signed, dated, and written informed c... [+20]

Has received any prior therapy with an anti-PD-1/PD-L1 antibody or an anti-cytot... [+27]

Status: Recruiting

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

The purpose of this study is to determine: 1. The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 2. The highest frequency of dosing of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 3. The highest dose and frequency of dosing of the trial intervention that targets neuroendocrine tumors with at least the same degree of effectiveness and tolerability as currently available (standard of care) treatments for patients with neuroendocrine tumors.

Participants needed: 36

Trial details

Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Peter Hosein, MDUpdated: Apr 28, 2026Locations: 1

Eligibility criteria

Male or female patients, 18 years of age or older at the time of consent. [+21]

Any active second malignancy within the 2 years prior to the screening visit, un... [+16]

Clinical trials

Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)